Department of Internal Medicine
Hematology, Oncology and Blood & Marrow Transplantation Faculty
Sarah Holstein, M.D., Ph.D.
Dr. Holstein’s clinical interests include multiple myeloma and other hematological malignancies as well as the application of clinical pharmacology to cancer therapeutics. Dr. Holstein’s laboratory research focuses on the development of novel agents for the management of multiple myeloma and understanding the roles of the intermediates and inhibitors of the isoprenoid biosynthetic pathway in plasma cell biology.
Honors, Awards, and Organizations
- Alpha Omega Alpha
- PhRMA Foundation 2010 Faculty Development Award in Clinical Pharmacology
- Celgene Future Leaders in Hematology Award
- American College of Physicians
- American Society of Hematology
- American Society of Clinical Oncology
- American Society of Clinical Pharmacology and Therapeutics
Recent Publications [view PubMed listing]
- Holstein, S.A. and Hohl, R.J. Vascular medicine: a look forward. Clinical Pharmacology and Therapeutics. 86: 117-9, 2009.
- Holstein, S.A., Tong, H., Kuder, C.H., and Hohl, R.J. Quantitative determination of geranyl diphosphate levels in cultured human cells. Lipids. 44: 1055-62, 2009
- Holstein, S.A., Tong, H., and Hohl, R.J. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leukemia Research. 34: 344-51, 2010